Palbociclib After CDK and Endocrine Therapy (PACE)
Public ClinicalTrials.gov record NCT03147287. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: * Fulvestrant * Fulvestrant with Palbociclib * Fulvestrant with Palbociclib and Avelumab
Study identification
- NCT ID
- NCT03147287
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 5, 2017 (Actual)
- Primary completion
- Dec 31, 2022 (Actual)
- Completion
- Dec 30, 2026 (Estimated)
- Last update posted
- Sep 11, 2026
2017 – 2026
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Miami | Miami | Florida | 33136 | — |
| Emory University - Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| The University of Kansas Cancer Center - North | Kansas City | Kansas | 64154 | — |
| The University of Kansas Cancer Center - Overland Park | Overland Park | Kansas | 66210 | — |
| The University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| Eastern Maine Medical Center | Bangor | Maine | 04401 | — |
| Boston Medical Center | Boston | Massachusetts | 02188 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Dana-Farber at St. Elizabeth's Medical Center | Brighton | Massachusetts | 02135 | — |
| DF/BWCC at Milford Regional Medical Center | Milford | Massachusetts | 01757 | — |
| DF/BWCC in clinical affiliation with South Shore Hospital | South Weymouth | Massachusetts | 02190 | — |
| The University of Kansas Cancer Center - Lee's Summit | Lee's Summit | Missouri | 64064 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Dana-Farber/New Hampshire Oncology-Hematology | Londonderry | New Hampshire | 03053 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Baylor University | Houston | Texas | 77030 | — |
| Aurora Cancer Care | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03147287, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03147287 live on ClinicalTrials.gov.